Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Use $1.5M US Army Grant to Develop Antiterrorist Devices

NEW YORK, Oct. 10 – Microarray technology developer Nanogen said on Wednesday it had received a three-year, $1.5 million grant from the US Army to develop devices to detect biological warfare and infectious disease agents in human blood samples.

Nanogen’s shares rose $2.88, or 52 percent, at $8.47 in afternoon trading on the Nasdaq following the news. 

Nanogen, based in San Diego, said it would develop miniaturized electronic devices that could isolate and detect agents that might be used in a terrorist attack. Nanogen said the U.S. Army Medical Research Institute of Infectious Disease at Fort Detrick, Md, would supervise the research.

"This agreement represents our continued commitment to the advancement of biological warfare defense, namely developing miniaturized electronic systems for rapidly detecting micro-organisms, DNA and protein substances that may be deployed as biological warfare agents," Randy White, CEO of Nanogen, said in a statement. 

The company said it would apply the technology developed under the grant to its commercial activities.

Genomics and other companies developing detection devices have also been among the bigger gainers on Wall Street recently. In the aftermath of the September 11 attacks on the World Trade Center and the Pentagon, concerns are growing about the possibility that terrorists could unleash a deadly round of biological and or chemical warfare.

On Tuesday, for example, shares of Cepheid and Bruker Daltonics rallied as investors sought stock in companies that might be at the forefront in the war against terrorism.

Cepheid is using genomics technologies to develop systems that could quickly detect bioterrorist agents, even before an attack. And Bruker Daltonics has developed Chemical Biological Mass Spectrometers that can be used to detect biological warfare agents. Several weeks ago, Bruker announced that it had received a $10 million contract from the United States Department of Defense for its spectrometers for chemical and biological defense. 

Shares of Cepheid and Bruker had both retreated by afternoon trading on Wednesday, with Bruker down $1.71, or 8.9 percent, at $17.50 and Cepheid down $0.31, or 3.8 percent, at $7.88.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.